Furthermore, there is an increasing trend for the consideration of the patient’s perspective in optimizing treatment access, as demonstrated in a real-world study, where patients’ self-perceived disease severity was utilized to explore key challenges in using TNF-α inhibitor biosimilars 29 .
← all excerpts
Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study).
1
—
—